REFERENCES
1. Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78:1922-65.
2. NCCN Clinical Practice Guidelines in Oncology-Hepatocellular Carcinoma. Available from: http://www.nccn.org [Last accessed on 23 Jan 2024].
3. Fan J. Alliance of Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma; Chinese College of Surgeons; Committee of Liver Cancer; Chinese Anti-Cancer Association;Liver Cancer Group; Society of Oncology, Chinese Medical Association. Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma(2023 edition). Chin J Dig Surg 2023;22:437-48.
4. Sun HC, Fan J, Zhou J, et al. Clinical practice status of the adjuvant therapy in hepatocellular carcinoma (HCC): a survey of Chinese hepatobiliary surgeons. J Clin Oncol 2022;40:e16127.
5. Bai X, Chen Y, Liang T. Preliminary data of a prospective study on the safety and efficacy of donafinib combined with anti-PD-1 antibody as adjuvant therapy for patients with hepatocellular carcinoma (HCC). J Clin Oncol 2022;40:e16131.
